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Nanoparticles are currently being investigated in a number of
human clinical trials. As information on how nanoparticles func-
tion in humans is difﬁcult to obtain, animal studies that can be
correlative to human behavior are needed to provide guidance for
human clinical trials. Here, we report correlative studies on
animals and humans for CRLX101, a 20- to 30-nm-diameter, multi-
functional, polymeric nanoparticle containing camptothecin (CPT).
CRLX101 is currently in phase 2 clinical trials, and human data from
several of the clinical investigations are compared with results
from multispecies animal studies. The pharmacokinetics of poly-
mer-conjugated CPT (indicative of the CRLX101 nanoparticles) in
mice, rats, dogs, and humans reveal that the area under the curve
scales linearly with milligrams of CPT per square meter for all spe-
cies. Plasma concentrations of unconjugated CPT released from
CRLX101 in animals and humans are consistent with each other after
accounting for differences in serum albumin binding of CPT. Urinary
excretion of polymer-conjugated CPT occurs primarily within the
initial 24 h after dosing in animals and humans. The urinary excre-
tion dynamics of polymer-conjugated and unconjugated CPT appear
similar between animals and humans. CRLX101 accumulates into
solid tumors and releases CPT over a period of several days to give
inhibition of its target in animal xenograft models of cancer and in
the tumors of humans. Taken in total, the evidence provided from
animal models on the CRLX101 mechanism of action suggests that
the behavior of CRLX101 in animals is translatable to humans.
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Multifunctional nanoparticles are emerging as a new class oftherapeutic agents (1). Several types of nanoscaled thera-
peutic agents such as PEGylated proteins, albumin-based for-
mulations, polymeric micelles, and liposomes are already approved
for human use, and these so-called “ﬁrst-generation” (2) nanoscaled
therapeutic agents have provided a basis for the design of newer
multifunctional nanoparticles (1–3). A small number of multi-
functional nanoparticles have been translated into clinical stud-
ies (4–9). These nanoparticles are less than 100 nm in diameter
and carry payloads such as small-molecule drugs, e.g., camp-
tothecin (CPT) (7), docetaxel (8), or siRNA (9). A few of these
nanoparticles also contain targeting ligands (8, 9) that aid in
their internalization into tumor cells. Some of the issues with
the use of targeting ligands such as added cost and complexity
have recently been described (10). These designed, multifunc-
tional nanoparticles are revealing interesting behaviors in early
clinical trials, e.g., they can signiﬁcantly reduce side effects of
the therapeutic molecules they carry, and they do not show new
side effects as a result of the nanoparticle.
Polymeric nanoparticles [as opposed to polymer–drug con-
jugates (1)] are currently undergoing clinical investigation for the
treatment of cancer (4–9, 11) and for use as vaccines (4, 5).
These clinical studies are providing initial information on the
behavior of sub–100-nm polymeric nanoparticles in humans. For
example, Davis et al. demonstrated that the amount of nano-
particles localized in melanoma tumors could be correlated to
the amount of the systemic dose administered to patients (9).
However, data on how nanoparticles function in humans are
difﬁcult to obtain. Thus, animal studies are used to provide
guidance. One key issue is whether the results from these animal
studies correlate with those in humans, i.e., what are the in-
terspecies variations in nanoparticle behavior? Therefore, there
is a large need to understand the relationships between the hu-
man and animal data, and to determine which behaviors in
humans can be reliably predicted from preclinical data with sub–
100-nm nanoparticles. Recently, data describing the formulation
of BIND-014 and its pharmacokinetic (PK) behavior in animals
and humans has been reported (8).
Here, we present translational data from the nanoparticle
denoted CRLX101 (formerly called IT-101). This multifunc-
tional nanoparticle is currently being investigated in a number of
phase 2 clinical trials for cancer. To our knowledge, CRLX101
was the ﬁrst de novo designed, polymeric nanoparticle to reach
the clinic (12).
CRLX101 is comprised of a cyclodextrin-containing polymer
conjugate of CPT (Fig. 1A). The cyclodextrin-containing poly-
mer was designed to have very high aqueous solubility with low
charge (ζ-potential of CRLX101 is ca. −6 mV in PBS solution),
as high charge (especially polycations) can create a number of
unwanted effects, including complement activation in mammals.
That way, the highly soluble polymer can be conjugated with very
low-solubility drugs. The cyclodextrin-containing polymer is
conjugated via glycine to the relatively insoluble CPT and
increases its effective solubility vs. that of the drug molecule
alone by approximately three orders of magnitude (12). The
linker chemistry can be tuned to provide a variety of release
behaviors. Speciﬁcally, the glycine linker used in CRLX101 was
chosen to provide slow release of the lactone form (the active
form) of CPT at acidic conditions that would be experienced
when the nanoparticles enter cells (12). The polymer strands
self-assemble into a nanoparticle (approximately ﬁve strands) of
approximately 20 to 30 nm diameter and 10 wt% CPT by mul-
tiple, interstrand, inclusion complex formation between cyclo-
dextrin and the CPT molecules (Fig. 1A).
CRLX101 has been shown to circulate in rodents with a t1/2 of
approximately 1 d (13, 14) and accumulate in solid tumor xen-
ografts as an intact nanoparticle (13). Additionally, the CRLX101
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nanoparticles have been observed [by transmission EM (TEM)
images] to localize into cancer cells in a mouse xenograft from
a tail vein injection (15). CRLX101 slowly releases the CPT when
inside cells to allow for long tumor exposures of the drug, and has
been observed to do so over several days in mouse xenografts (16).
Released, active CPT from CRLX101 has resulted in indications
of prolonged topoisomerase I and HIF-1α inhibition (targets of
CPT) in mouse xenografts (15, 16), and has provided increased
antitumor activity compared with irinotecan and topotecan (both
are Food and Drug Administration-approved analogues of CPT)
(12, 15–17). The CRLX101 nanoparticle is designed to disas-
semble when the CPT is released to give individual polymer
strands that are synthesized to have molecular weights sufﬁciently
small to allow for clearance via the kidney (Fig. 1B) (12, 13).
Herein, we present results from phase 1a, 1b, and 2a (7)
clinical trials and correlate them to animal data to elucidate how
the multifunctional behavior of CRLX101 translates from ani-
mals to humans.
Results
Preclinical and Clinical Lots of CRLX101 Give 20- to 30-nm-Diameter
Nanoparticles. The synthesis and properties of preclinical nano-
particles of CRLX101 have been described previously (12–18).
The nanoparticles were 20 to 30 nm in diameter, and charac-
terization studies demonstrated that all the polymer chains were
contained within the nanoparticles (i.e., no free polymer chains)
(13). A schematic of the process for the synthesis and formula-
tion of CRLX101 into vials is provided in SI Appendix, Fig. S1.
Various lots of CRLX101 were prepared and used in clinical
studies. A summary of some of these lots and their properties is
given in SI Appendix, Table S1. Similar to the preclinical versions
of CRLX101, clinical lots A, B, and E tested negative for the
presence of free polymer chains.
Because the nanoparticles are composed of organic material
and are quite small, measurements of size via dynamic light
scattering (DLS) can be difﬁcult. To verify sizes measured by
DLS and determine accurate size distributions, several lots were
imaged by using cryo-TEM. A representative image and the size
distributions for two lots are provided in SI Appendix, Figs. S2–S5.
In general, there is good agreement between the DLS nano-
particle sizes and those measured by cryo-TEM (SI Appendix,
Table S1 and Figs. S3–S5). Also, the mean value of the size and
the size distributions by DLS or cryo-TEM vary only slightly from
lot to lot (SI Appendix, Table S1 and Figs. S3–S5).
Human Plasma PK Shows Long Circulation of the Nanoparticles and
Areas Under the Curve of Polymer Conjugated CPT Scale Linearly with
Dose. CLRX101 was administered to patients as 60- to 90-min
infusions (7). Fig. 2A shows the mean plasma concentrations of
the payload CPT that is conjugated to the polymer of CRLX101
and CPT that is not conjugated to the polymer (i.e., was released
from the polymer) for several dose levels from the phase 1a
clinical trial. For the conjugated CPT, the maximum concen-
tration is observed within 2 h of ending the infusion, whereas the
maximum concentration of the unconjugated CPT occurs at
a much later time. A summary of the PK data is listed in SI
Appendix, Table S2. The patient-to-patient variations in the PK
parameters at any given dose level are small (7), and the area
under the curve (AUC) for the conjugated or unconjugated CPT
increases in a linear fashion with the dose in milligrams of CPT
per square meter (Fig. 2B).
Animal and Human AUCs Scale Linearly with Dose. Fig. 3 illustrates
the striking similarity of PK parameters obtained from rats and
dogs (Fig. 3 A and B) and humans (Fig. 3C) for the conjugated
CPT. Fig. 3D shows data that demonstrate that the AUC of the
polymer-conjugated CPT scales linearly with milligrams of CPT
per square meter, and that the results from animals and humans
follow the same relationship.
Animal and Human PK Parameters Are Unchanged upon Repeat
Dosing. The data displayed in Fig. 3 A–C show that, after re-
peat dosing, there are no appreciable changes in the PK for the
polymer-bound and unconjugated CPT in any of the animal or
human studies. Human PK parameters were measured for con-
jugated and unconjugated CPT after the ﬁrst dose of CRLX101
to the patient and after the ﬁrst dose of the sixth monthly cycle,
i.e., the eleventh dose of CRLX101. No statistically signiﬁcant
differences are observed between the PK parameters from re-
peat dosing (SI Appendix, Table S3), and no intrapatient changes
are observed in AUC or clearance (SI Appendix, Fig. S6).
Fig. 1. Schematic diagrams of the assembly and disassembly of CRLX101. (A) Schematic of the cyclodextrin-containing polymer conjugate of CPT and its
components. (Right) Cryo-TEM of the CRLX101 nanoparticles formed by self-assembly of the polymer–drug conjugates. (B) Schematic of CRLX101 assembly
and disassembly (when the CPT is released).
Fig. 2. Human plasma PK parameters. (A) Plasma concentrations of conju-
gated CPT (closed symbols) and unconjugated CPT (open symbols) as a function
of time from the phase 1a clinical trial. Data points represent mean, and error
bars represent SD (n = 6 per dose level). Circles, 6 mg/m2; squares, 12 mg/m2;
triangles, 15 mg/m2; diamonds, 18 mg/m2. (B) AUC as a function of dose level
for conjugated CPT (closed symbols) and unconjugated CPT (open symbols).
Data points represent mean, and error bars represent SD (n = 6 per data
point). CRLX101 lots A and E were used in this study.
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PK of Unconjugated CPT Depends on Its Binding to Serum Albumin.
The time-dependent behavior of the conjugated CPT appears
similar between animals and humans (Fig. 3 A–C). However, this
is not the case for the unconjugated CPT. The dynamics in the
human are not what are observed in the various animals models
(the interspecies animal data are consistent). To provide a plau-
sible explanation for these data, the dynamics of the conjugated
and unconjugated CPT were modeled (SI Appendix, Supplementary
Materials and Methods). The simulations (SI Appendix, Figs. S7
and S8) are able to recapitulate the experimental observations,
and suggest that the differences in the human dynamics of un-
conjugated CPT result from the high binding afﬁnity between
human albumin and CPT [CPT binds with higher afﬁnity to
human albumin than albumin from other species (19)]. After
taking into account these interspecies variations in albumin
binding, the unconjugated CPT PK in humans can be correlated
with the preclinical animal data.
PK Is Inﬂuenced by Nanoparticle Drug Loading but Not Polymer
Molecular Weight. Polymer molecular weight and drug loading
are two key parameters that are controlled and measured during
the formulation of CRLX101. To understand how these nano-
particle properties correlate with PK, the polymer molecular
weight and drug loading of several nanoparticles were varied to
give high and low bounds for investigation. The PK of these
nanoparticles were measured in rats, and the results are listed in
SI Appendix, Table S4. The rat PK data suggest that a 50% re-
duction in drug loading accelerates the release of CPT from the
nanoparticles, as reﬂected by increases in the AUC of un-
conjugated CPT. This result is consistent with the important role
that the cyclodextrin–CPT inclusion complex plays in stabilizing
CRLX101. With increasing CPT conjugated to the polymer, the
nanoparticles are more highly stabilized by a larger number of
inclusion complexes. In contrast, changes in polymer molecular
weight (over the range investigated) had minimal effects on PK.
The manufacturing process of CRLX101 for clinical use is
remarkably consistent, and polymer molecular weight and drug
loading do not appreciable vary from lot to lot (SI Appendix,
Table S1). Although several different lots of CRLX101 were
administered to patients over the course of the phase 1 and 2a
clinical trials, minimal impact of lot variations on PK was ob-
served. SI Appendix, Table S5, lists PK data from patients who
received two different lots of CRLX101 in the phase 2a trial.
CPT (Nanoparticle Drug Payload) Release from CRLX101 Is Not via
Esterase Activity. The CPT in CRLX101 is conjugated to the
polymer via an ester bond (Fig. 1A), and, when this bond is
cleaved, CPT is released. When a critical number of the CPT
molecules are removed from the polymer chain, that chain can be
lost from the nanoparticle (nanoparticle disassembly; Fig. 1B). To
ascertain whether esterase activity could contribute to the release
of CPT, the in vitro release kinetics were measured. In all cases,
the release kinetics were ﬁt to a ﬁrst-order process. The t1/2 values
for CPT release in mouse serum that was freshly collected or
frozen at some point were 51 and 49 h, respectively. Thus, the
freezing of serum has no effect on the release kinetics. The t1/2 that
was measured from human serum that had been frozen was 26 h.
Mouse serum has more esterases than human serum (20). As
the release of CPT from CRLX101 is faster in human serum than
mouse serum, these results suggest that esterase activity is not
the main pathway for CPT release. To further this idea,
CRLX101 was tested in vitro in the presence of just butyr-
ylcholinesterase (BCHE) in PBS solution because it is contained
in mouse and human serum (20). The release t1/2 of the CPT was
not signiﬁcantly different in the absence or presence of BCHE. If
LDL is added at an amount of 3 mg/mL into PBS solution, the t1/2
is 35 h (greater than 100 h in PBS solution alone), and is the same
in the presence and absence of BCHE. Taken together, these data
suggest that the release of CPT is through the hydrolysis of the
ester bond (independent of enzyme activity), and that the pres-
ence of lipoprotein complexes like LDL can assist in the disas-
sembly of CRLX101. If the release kinetics of CPT are the result
of hydrolysis rates, they should be a function of pH. The release
kinetics of CPT from CRLX101 have been shown to be pH-
dependent, with longer t1/2 values being observed for lower pH
values (18). These data suggest that differences in interspecies CPT
release kinetics are caused by differences in plasma contents, such
as lipoprotein complexes, as opposed to levels of plasma esterases.
CPT and Polymer Conjugated CPT Are Excreted into the Urine.Within
the ﬁrst 8 h after infusion, greater than 10% of the administered
dose of CRLX101 was excreted into the urine as conjugated CPT
(7). Interestingly, the percentage of the dose excreted declines
with increasing dose (7), raising the possibility that the renal
excretion processes become saturated. Data provided in Fig. 4
show that the excretion of conjugated CPT reaches a maximum
at 15 mg/m2.
Patients dosed with more than one lot of CRLX101 during
their course of treatment did not show signiﬁcant differences in
the amount of CPT excreted (SI Appendix, Fig. S9). Analyses of the
polymer molecular weight from polymer collected from the patient’s
urine revealed that the molecular weight distribution was not sta-
tistically different from that of the CRLX101 that was administered.
CRLX101 Accumulates in and Penetrates Through Tumors to Release
Functional CPT. Some important characteristics of nanoparticles
include their ability to prolong drug plasma t1/2 , to penetrate into
tumors via the leaky tumor neovasculature, and to accumulate in
tumors as a result of the enhanced permeation and retention
effect. In order for these nanoparticle characteristics to translate
to superior efﬁcacy, however, it is also beneﬁcial for the nano-
particle to penetrate deep into tumors to kill tumor cells localized
far from the vasculature.
By using the intrinsic ﬂuorescence of the CPT component of
CRLX101, Fig. 5 A and B shows images that illustrate that
Fig. 3. Interspecies CRLX101 PK comparison. (A and B) Plasma concen-
trations of conjugated CPT (closed symbols) and unconjugated CPT (open
symbols) as a function of time in rats (A) and dogs (B). Circles represent ﬁrst
dose, and squares represent third weekly dose. Data points represent mean,
and error bars represent SD (n = 6 per data point). (C) Plasma concentrations
of conjugated CPT (closed symbols) and unconjugated CPT (open symbols) as
a function of time from the phase 2a clinical trial. Circles represent ﬁrst dose,
and squares represent 11th biweekly dose (cycle 6, day 1). Data points rep-
resent mean, and error bars represent SD. (D) AUC as a function of dose level
across species for conjugated CPT. The line is a linear regression against all
data points (R2 = 0.802). Data points represent mean, and error bars rep-
resent SD (n = 6 per data point). Squares, rat; triangles, dog; diamonds,
human. Closed symbols, male; open symbols, female.
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CRLX101 begins to enter tumors of mouse xenografts within 6 h
after dosing, and remains in the tumors over several days while
diffusing away from the tumor vasculature. By using an anti-PEG
antibody, we conﬁrm that CRLX101 deposits in tumors as as-
sembled nanoparticles by showing that CPT and polymer compo-
nents of CRLX101 are colocalized in tumors (Fig. 5C). Once in
tumors, the drug payload CPT is released slowly from CRLX101,
and can signiﬁcantly inhibit topoisomerase-1 for as long as 1 wk
after a single, submaximal dose (Fig. 5D). HIF-1α is also inhibited
in this study (SI Appendix, Fig. S12), consistent with previously
published data (15).
Fig. 5E shows an image of CPT signal detected in a tumor
biopsy sample taken from a patient with gastric adenocarcinoma
48 h after CRLX101 treatment. The pattern of CPT ﬂuorescence
observed in this biopsy specimen is consistent with that seen in
the animal models, suggesting that the CPT signal detected with
this patient’s tumor is from intact CRLX101.
Discussion
CRLX101 is a polymer-based nanoparticle of designed size and
ζ-potential. The diameter of approximately 20 to 30 nm allows
for movement through solid tumors (13, 21) and the slightly
negative ζ-potential at this size helps to minimize uptake by the
mononuclear phagocyte system (22). CRLX101 is designed
to have high solubility, to circulate and extravasate into solid
tumors via their leaky vascular as an intact nanoparticle (13, 15),
to enter cancer cells, and to slowly release the active form of
CPT for extended periods of time to enhance its mechanism of
action (16). The polymer component of CRLX101 is synthesized to
be small enough to clear the body via renal excretion after the
nanoparticle disassembles into individual polymer strands (Fig. 1B).
There are numerous data from animals that support the con-
clusion that CRLX101 remains as intact nanoparticles in circula-
tion. PET studies of CRLX101 show that polymer-conjugated
CPT has a t1/2 of approximately 24 h in mice, and that the mea-
sured tumor permeability data are consistent with an approxi-
mately 30-nm nanoparticle and not an individual polymer strand
(13). Additionally, PET-labeled single polymer strands cleared
from mice via urinary excretion in less than 1 h. Imaging of mouse
tumors indicates that CRLX101 does reach tumors intact (13),
and high-resolution TEM images reveal direct visual evidence for
intact nanoparticles within tumor cells (15). Thus, we will refer to
the polymer-conjugated CPT as the nanoparticle CRLX101.
The PK of CRLX101 in humans (Fig. 2A) revealed excellent
reproducibility from patient to patient (7). Additionally, the AUC
of the polymer-conjugated and unconjugated CPT increased in
a linear, dose-dependent manner (Figs. 2B and 3D). The long
circulation of CRLX101 provides extended time for the nano-
particles to extravasate into solid tumors via their leaky vascula-
ture (13). The circulation time in humans was such that patients
receiving weekly doses of CRLX101 in the phase 1 clinical trial
were experiencing “carryover” of CPT from previous dosing (7).
To eliminate the carryover, the administrations were altered to
dosing on a biweekly schedule. Patients receiving CRLX101
doses of 15 mg CPT/m2 on the biweekly schedule showed no
polymer-conjugated CPT at 14 d after administration, and, for
the unconjugated CPT, they had only 3.1% remaining of the
mean maximum concentration (Cmax) values (7). This dosing
amount and schedule is being used for all phase 2 clinical trials.
In the phase 1 and 2a clinical trials of CRLX101, biweekly
dosing appears to be well tolerated, no incremental toxicities
were observed with long-term (>6 mo) treatment, and the poly-
mer does not appear to contribute to toxicity (7). As shown in the
data provided in Fig. 3 and SI Appendix, Table S3, there were no
effects of treatment cycle on the PK parameters in humans and
animals. Thus, it is expected that clearing antibody formation to
CRLX101 is not occurring to any signiﬁcant amount. These
results show that the multicycle animal data are predictive of the
multicycle data observed in humans. In contrast, PEGylated lip-
osomes have produced hypersensitivity reactions, complement
activation, and other side effects that are not observed from the
drug alone (23, 24). Additionally, cycle-dependent PK parameters
have been observed for PEGylated doxorubicin in humans (i.e.,
the clearance decreased over three cycles of treatment) (25).
Factors inﬂuencing the intrapatient and interpatient PK param-
eters with liposomes are discussed elsewhere (26, 27).
CRLX101 PK results from several animal studies and the clinical
data from humans demonstrate that the AUC is linear with dose
on the basis of milligrams of CPT per square meter (Fig. 3D).
These data suggest that interspecies scaling can be done on body
surface area. This conclusion is important, as there have not
been data available to assess what the proper interspecies scaling
should be for polymer-based nanoparticles. Other nanoparticles
have shown this type of scaling in humans. For example, Hamaguchi
et al. reported from their phase 1 study that the AUC of the poly-
meric micelle NK105 increases linearly with dose in milligrams per
square meter (28). Likewise, Lim et al. reported that the AUC for
the polymeric micelle Genexol-PM increases linearly with dose in
milligrams per square meter (29). However, we are not aware of
data like those displayed in Fig. 3D that show the scaling between
animals and humans is the same when based on milligrams of CPT
per square meter.
The human PK dynamics of unconjugated CPT are not con-
sistent with the animal species amounts and dynamics. We have
modeled these dynamics (SI Appendix, Supplementary Materials
and Methods), and the results suggest the different human dy-
namics are mainly attributable to the much higher binding af-
ﬁnity of CPT to human albumin than the albumin in other
species (19). This high binding to human albumin is not observed
with the active metabolic of irinotecan, SN-38 (30, 31). When
CPT was conjugated to linear PEG, the PK proﬁles of the re-
leased CPT in animals (32) and humans (33, 34) showed the
same form of the dynamics as observed for CRLX101. Likewise,
the MAG-CPT gave released CPT dynamics of the same type
(35, 36). However, the polymeric micelle of SN-38 shows the
same behavior for released SN-38 in animals (37) and humans
(28), as does PEG-bound SN-38 in animals (38) and humans
(39). When CPT binding to albumin is properly accounted for,
the PK parameters of the unconjugated CPT in animals and
humans can be correlated.
A major issue in the translation of nanoparticle therapeutic
agents is that of how lot-to-lot (i.e., preparation-to-preparation)
variations affect performance. Initially, the PK parameters in
rats were investigated as a function of polymer molecular weight
and drug loading, as these parameters are critical to the for-
mulation and performance of CRLX101. High and low values for
polymer molecular weight and CPT loading were chosen to de-
ﬁne a parameter space larger than expected from the lot-to-lot
variations in clinical-grade CRLX101. These parameters and the
resulting PK data obtained in rats are given in SI Appendix, Table S4.
There were no appreciable differences in the rat PK parameters
Fig. 4. Urinary excretion of conjugated and unconjugated CPT as a function
of dose level. Collection periods are 0 to 24 h (A) and 24 to 48 h (B). Total drug
content was measured and normalized to the body surface area for each
patient. Shaded bars represent conjugated CPT, and open bars represent un-
conjugated CPT. Data points represent mean, and error bars represent SD.
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when the polymer molecular weight was varied. However, a 50%
reduction in CPT loading increased the AUC of unconjugated
CPT in rat PK experiments, presumably by destabilizing the
nanoparticles and allowing for faster release of CPT. Given this
information, the lot-to-lot variations on CPT loading in the clin-
ical CRLX101 samples were kept to a minimum (SI Appendix,
Table S1). The PK data from humans for two different lots of
CRLX101 (SI Appendix, Table S5) demonstrate that changes in
nanoparticle size and loading in different clinical batches did not
result in major differences in the human PK (and also urinary
excretion; SI Appendix, Fig. S9).
CRLX101 is designed to disassemble when CPT is released from
the nanoparticles. Previous studies have shown that CRLX101
drug–polymer conjugate strands are fully incorporated into nano-
particles with no free, low molecular weight conjugate present in
the formulation (13). Several clinical lots of CRLX101 were also
tested for free polymer conjugate, and none were detected. A
prolonged plasma t1/2 of CRLX101 facilitated by a nanoparticle
size that exceeds the kidney ﬁltration limit of approximately 10 nm
suggests that the source of polymer-bound CPT in urine is from
individual drug–polymer strands after nanoparticle disassembly.
Apparently, disassembly does not require that all the drug mole-
cules be released from each strand. When disassembly has oc-
curred, these partially drug-bound polymer strands are small
enough that they would pass rapidly through the kidney. The mo-
lecular weight of the polymer that is excreted into the urine is the
same as in the dosed CRLX101; therefore, there is no fractionation
of the polymer strands by molecular weight in the human. The
release of CPT from CRLX101 is via hydrolysis, but serum com-
ponents appear to be able to interact with the nanoparticles to
increase the availability of the CPT for release, and are likely ac-
countable for some of the differences in the release kinetics between
animals and humans. In humans, the urinary excretion appears to
involve some process that can be saturated. At this time, it is not
clear what this process is. However, it is important to point out
that no toxicities of the kidney are observed in any of the clinical
studies reported thus far (7).
No human biodistribution data are available. However, the
biodistribution of CRLX101 has been investigated in animals,
and accumulations in kidney, liver, and spleen are observed in
addition to tumor (13, 14). In mice, the total amount of CPT per
gram of tissue (14) and polymer (that is indicative of CRLX101
nanoparticles) are the highest in the tumor tissue at 24 h after
administration (13). Urinary excretion of polymer-conjugated
CPT occurs primarily within the initial 24 h after dosing in ani-
mals and humans. Given that the PK and urine excretion dy-
namics in animals and humans are correlated, it is expected that
the human biodistribution should be similar to that observed
in animals.
The safety proﬁle of CRLX101 at the maximum tolerated dose
of 15 mg CPT/m2 administered biweekly has been reported (7).
Overall, CRLX101 is very well tolerated, and the side effects
obtained are attributable to the known side effects of CPT. No
new side effects of the nanoparticle are observed (7). Thus, it is
most likely that the side effects from administering CRLX101 in
humans are from the payload and not from the nanoparticle itself.
Accumulation of CRLX101 into mouse tumor xenografts has
been investigated previously (13–16), and the time-dependent
localization in one tumor type is illustrated in Fig. 5 A and B. The
nanoparticles are shown to move away from tumor vasculature
and reside in the tumor for many days. The slow release of CPT
has been reported previously (16), and here it is shown that the
released CPT can signiﬁcantly inhibit topoisomerase-1 activity
for as long as 1 wk after a single, submaximal dose (Fig. 5D). A
biopsy of a human gastric adenocarcinoma revealed CPT signal
was present 48 h after CRLX101 administration (Fig. 5E). The
pattern of distribution of CPT signal observed in the human
gastric tumor was similar to the pattern of distribution of
CRLX101 observed in the mouse xenografts. Additionally, a tu-
mor biopsy from a patient with triple-negative breast cancer
receiving CRLX101 dosing of 15 mg CPT/m2 revealed the
presence of CPT 14 d after dosing (7). This long tumor exposure
of CPT in humans is consistent with data from previous animal
models (16) and those shown in Fig. 5.
Fig. 5. CPT in tumors of mice and humans. (A and B) Fluorescence microscopy demonstrates tumor penetration of CRLX101 over 1 wk following a single dose
in NCI-H2122 KRAS mutant non–small-cell lung cancer xenografts. Yellow color is CPT ﬂuorescence (SI Appendix, Fig. S10, shows excitation spectrum), and
blue color is (A) nuclei or (B) blood vessels stained with anti-CD31. CPT ﬂuorescence is maximal at 24 h and still detectable at diminished levels at 168 h. CPT
ﬂuorescence is more tightly associated with blood vessels at earlier time points. (C) Fluorescence microscopy demonstrates polymer (anti-PEG antibody) and
CPT ﬂuorescence colocalization, suggesting that CPT ﬂuorescence signal in the tumor comes from intact CRLX101 nanoparticles. (D) Prolonged tumor ex-
posure to CPT correlates with prolonged inhibition of topoisomerase-1 (SI Appendix, Fig. S11). Mice bearing NCI-H1299 non–small-cell lung cancer tumors
were dosed once with 6 mg/kg CRLX101, and tumors were harvested and analyzed at the times indicated for CPT concentration (squares) and topoisomerase-1
expression (circles). CPT concentrations were measurable for >2 wk after a single dose, and topoisomerase-1 inhibition was evident for >1 wk, demonstrating
sustained release of CPT in tumors. (E) Detection of CPT ﬂuorescence in a tumor biopsy sample taken from a patient with gastric adenocarcinoma 48 h after
CRLX101 treatment. CPT signal is bright green (punctate green dots) and not observed in the pretreatment tumor biopsy.
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Taken in total, the evidence provided from animal models on
the CRLX101 mechanism of action suggests that the nano-
particle behavior in animals is translatable to humans. Although
there are interspecies differences that need to be accounted for,
such as the serum albumin binding of CPT and plasma compo-
nents that affect the CPT release kinetics, the overall PK and
pharmacodynamic parameters from animals and humans do
appear to be correlated.
Materials and Methods
Complete details of materials and methods are provided in SI Appendix,
Supplementary Materials and Methods.
Synthesis of CRLX101 for Rat PK Study. CRLX101 was synthesized by using
methods described elsewhere (18).
Cryo-TEM Imaging. Images were collected on a Tecnai 120-keV transmission
electron microscope (FEI Company) equipped with a Gatan 2k × 2k UltraScan
CCD camera (Gatan).
CRLX101 In Vitro Release Kinetics. Release of CPT from CRLX101 was conducted
at 0.32 mg CPT/mL in BALB/c mouse plasma, human plasma, and PBS solution,
pH 7.4, in the presence and absence of 100 U/mL of BCHE and/or 3 mg/mL LDL.
Plasma and Urine PK Study in Rat, Dog, and Human. Rats were dosed at 2.59
mg/kg (Fig. 2) or 3 mg/kg CRLX101 (CPT equivalent), and beagle dogs were
dosed at 0.58 m/kg CRLX101 (CPT equivalent) by i.v. injection. Patients from
the phase 1 and 2a clinical trials were dosed as described previously (7). Patient
urine was analyzed for conjugated and released CPT by using methods de-
scribed elsewhere (7).
Mouse Tumor PK Study. Tumor samples were homogenized in 1:1 DMSO:
water, 0.1% formic acid. The homogenates were centrifuged, and the su-
pernatant was collected for processing.
Measurement of Mouse Tumor Topoisomerase-1. At the time points indicated,
mice were killed, and tumors were harvested and homogenized for immu-
noblotting. Immunoblotting was performed by using anti-topoisomerase 1
(1:1,000; Abcam) and anti-actin (1:2,500; Santa Cruz) antibodies. IRDye-
conjugated anti-mouse and anti-rabbit secondary antibodies (1:10,000; LI-
COR) were visualized on the Odyssey CLx infrared imaging system.
Tumor Penetration. At the time points indicated, mice were killed and the
tumors were embedded in optimal cutting temperature compound and
frozen. All mice were treated according to the National Institutes of Health
Guidelines for Animal Care and Use as approved by the Caltech Institutional
Animal Care and Use Committee. Human gastric adenocarcinoma sample was
obtained from a patient enrolled in a CRLX101 pilot trial with consent in
accordance with City of Hope Institutional Review Board (IRB) guidelines (City
of Hope IRB Protocol 11276). The biopsy specimens were immediately frozen
in optimal cutting temperature media on dry ice, and transferred to the City
of Hope Translational Research Laboratory before processing. Sections of
mouse xenografts and the human tumor biopsies were imaged on a Zeiss
LSM 510 inverted confocal scanning microscope (PlanApochormat ×63/1.4 oil
objective; Zeiss).
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